Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis

Oct 07 2021

• By Jessica Merrill

Time out hands — Bristol's TYK2 inhibitor failed a Phase II study in ulcerative colitis • Source: Alamy

Related Content

Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI

May 28 2021

FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands

Sep 01 2021

Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III

Nov 04 2020

Related Companies

Bristol Myers Squibb Company

Amgen, Inc.

Pfizer Inc.

AbbVie Inc.

Eli Lilly and Company

Additional Topics

Research & Development Clinical Trials Companies Business Strategies Immune Disorders BioPharmaceutical

More from Immunological

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.